As of 2022, in nearly every country in Europe, over half of adults were classed as overweight or obese. The highest rate was recorded in Romania, with ** percent of adults self-reporting as overweight or obese. In both Croatia and the United Kingdom, around ** percent of adults had a BMI of over **. Europe one of the worst affected regions Europe had the second-highest number of obese adults across the WHO regions, only behind the region of the Americas. Over *** million adults aged 20 years were classed as obese in Europe in 2020. The number of obese adults in Europe was forecast to grow to *** million by 2035. Problems also with childhood obesity In 2020, ** million children in Europe were overweight, the highest across all continents. It was forecast with current trends that, by 2035, *** million children would be overweight. A further ** million children across the continent were classed as obese. Children that are overweight or obese are at a higher risk of developing numerous health conditions, such as type 2 diabetes, asthma, and high blood pressure.

This statistis displays the growth in obesity rates in selected European countries in 1975 and 2014. The obesity rate in Ireland grew from *** percent in 1975 to **** percent in 2014.

This indicator is derived from the body mass index (BMI), which is defined as the weight in kilograms divided by the square of the height in metres. People aged 18 years or over are considered obese if their BMI is equal to or greater than 30. The category ‘pre-obese’ refers to people with a BMI between 25 and less than 30. The category ‘overweight’ (BMI equal or greater than 25) combines the two categories pre-obese and obese. The data presented in this section stem from the European Health Interview Survey (EHIS) and the EU Statistics on Income and Living Conditions (EU-SILC).

Historical dataset showing European Union obesity rate by year from N/A to N/A.

By 2030, Hungary, Turkey, and Croatia were projected to have the highest prevalence of childhood obesity (between 5 and 19 years of age) across Europe at 19 percent. Across the whole of Europe, it was projected that just over 16 percent of children aged between five and nine years of age would be classed as obese by 2030.

This statistic displays the obesity prevalence among children in selected countries in Europe in 2016. That year, ****% of children in Greece were obese.

The indicator measures the share of obese people based on their body mass index (BMI). BMI is defined as the weight in kilos divided by the square of the height in meters. People aged 18 years or over are considered obese with a BMI equal or greater than 30. Other categories are: underweight (BMI less than 18.5), normal weight (BMI between 18.5 and less than 25), and pre-obese (BMI between 25 and less than 30). The category overweight (BMI equal or greater than 25) combines the two categories pre-obese and obese.

Overweight and obesity prevalence rates estimates (1975-2016)

By 2025, the prevalence of obese children in Greece is projected to reach **** percent, this would be the highest childhood obesity prevalence across all countries in the EU and the UK. Hungary with **** percent was forecast to have the second-highest prevalence of childhood obesity in Europe, followed by Croatia at **** percent.

This statistical report presents a range of information on obesity, physical activity and diet, drawn together from a variety of sources.

The topics covered include:

• Overweight and obesity prevalence among adults and children

• Physical activity levels among adults and children

• Trends in purchases and consumption of food and drink and energy intake

• Health outcomes of being overweight or obese.

This report contains seven chapters which consist of the following:

• Chapter 1: Introduction; this summarises government policies, targets and outcome indicators in this area, as well as providing sources of further information and links to relevant documents.

• Chapters 2 to 6 cover obesity, physical activity and diet and provides an overview of the key findings from these sources, whilst maintaining useful links to each section of these reports.

• Chapter 7: Health Outcomes; presents a range of information about the health outcomes of being obese or overweight which includes information on health risks, hospital admissions and prescription drugs used for treatment of obesity.

• Figures presented in this report have been obtained from a number of sources and presented in a user-friendly format. Some of the data contained in the chapter have been published previously by the Health and Social Care Information Centre (HSCIC). Previously unpublished figures on obesity-related Finished Hospital Episodes and Finished Consultant Episodes for 2012-13 are presented using data from the HSCIC's Hospital Episode Statistics as well as data from the Prescribing Unit at the HSCIC on prescription items dispensed for treatment of obesity.

As per Cognitive Market Research's latest published report, the Global Anti Obesity Drugs market size was XX Million in 2025 and it is forecasted to reach XX Million by 2033. Anti Obesity Drugs Industry's Compound Annual Growth Rate will be XX% from 2025 to 2033.

North America held largest share of XX % in the year 2024 
Europe held share of XX % in the year 2024 
Asia-Pacific held significant share of XX % in the year 2024 
South America held significant share of XX % in the year 2024
Middle East and Africa held significant share of XX % in the year 2024

Market Dynamics of the Anti Obesity Drug Market

Market Drivers of the Anti Obesity Drug Market

Rising prevalence of obesity significantly boost the anti obesity drug market growth

The rising prevalence of obesity has been a significant driver behind the growth of the anti-obesity drug market. Obesity rates have been steadily rising worldwide over the past few decades, reaching epidemic proportions in many countries. This rise is attributed to a combination of factors, including changes in dietary habits, sedentary lifestyles, urbanization, and socioeconomic factors. As a result, obesity has become a major public health concern, leading to an array of associated health problems such as type 2 diabetes, cardiovascular diseases, and certain types of cancer.

For Instance, in 2022, one in eight people in the world has the problem of obesity. In all over the world obesity has more than doubled. 2.5 billion adult who is 18yrs and older were overweight. Of this people ,890 million were living with obesity. 43% of adult who as the obesity there aged 18 years. 37 million children under the age of 5 were overweight.

The obesity epidemic has led to a number of negative effects, one of which is an increase in the need for efficient weight-management programs that also enhance general health. Even though diet and activity changes are still the cornerstones of obesity therapy, certain people may not always benefit from them, especially if they have underlying metabolic problems or are extremely obese. Pharmaceutical companies now have a huge window of opportunity to develop and market anti-obesity medications that can supplement conventional therapies.

For example, medications such as liraglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor, and orlistat, which slows the absorption of dietary fats, have been licensed for the long-term management of weight in obese individuals or those with overweight and obesity-related comorbidities. These medications have shown promise in enhancing metabolic parameters and encouraging weight loss, making them useful additions to the arsenal of treatments for obesity.

The pharmaceutical sector has also increased its research and development efforts to find new therapeutic targets and create cutting-edge anti-obesity medications as a result of the obesity epidemic. To find viable treatment targets, this entails looking into the processes underpinning energy metabolism, appetite control, and fat storage. Innovation in the field of drug development has been further stimulated by technological advancements like high-throughput screening and computer modeling, which have sped up the identification and optimization of therapeutic candidates.

Additionally, the financial burden of obesity-related medical expenses has encouraged politicians and healthcare systems to fund initiatives that can lessen the negative effects of obesity on public health. This involves providing funds for research, regulatory incentives, and reimbursement policies to assist the development and accessibility of anti-obesity medications. Pharmaceutical companies are attempting to address the growing demand for efficient obesity therapies, which has led to a surge in investment and market expansion in the anti-obesity medicine market.

Thus, the increasing prevalence of obesity has acted as a catalyst for the growth of the anti-obesity drug market by creating a greater demand for effective treatments, fostering innovation in drug development, and attracting investment from stakeholders across the healthcare ecosystem. As the obesity epidemic continues to pose a significant health challenge globally, the market for anti-obesity drugs is expected to expand further, offering new opportunities for therapeutic advancement and improved patient outcomes. &ems...

Obesity Treatment Devices Market Outlook

The global obesity treatment devices market size was valued at approximately USD 1.8 billion in 2023 and is projected to reach around USD 4.1 billion by 2032, growing at a robust CAGR of 9.4% during the forecast period. The increasing prevalence of obesity worldwide, coupled with advancements in medical technology and a growing awareness regarding the health risks associated with obesity, are key driving factors contributing to the market growth. Additionally, the increasing acceptance and adoption of minimally invasive procedures for weight loss are further propelling the market expansion.

One of the critical growth drivers for the obesity treatment devices market is the rising obesity rates across the globe. According to the World Health Organization (WHO), obesity has nearly tripled since 1975, with over 650 million adults classified as obese in 2016. This alarming rise is primarily attributed to sedentary lifestyles, unhealthy diets, and genetic factors. The increasing obesity prevalence is pushing healthcare systems and governments to invest heavily in obesity management and treatment solutions, thereby fueling the demand for obesity treatment devices.

Technological advancements in obesity treatment devices are also significant contributors to market growth. Innovations such as adjustable gastric bands, minimally invasive gastric balloons, and advanced electrical stimulation systems offer effective, less invasive, and safer alternatives to traditional bariatric surgery. These advancements have improved patient outcomes, reduced recovery times, and minimized complications, making them more appealing to both patients and healthcare providers. Consequently, the adoption of these advanced devices is expected to witness substantial growth in the coming years.

Public awareness and government initiatives aimed at combating obesity are further enhancing the market outlook. Various health organizations and government bodies are launching campaigns and programs to educate people about the health risks of obesity and the available treatment options. These initiatives not only promote healthier lifestyles but also encourage individuals to seek medical interventions, thereby driving the demand for obesity treatment devices. Additionally, favorable reimbursement policies and increasing healthcare expenditure in developed and developing regions are expected to boost market growth.

From a regional perspective, North America currently holds the largest market share in the obesity treatment devices market, followed by Europe and Asia Pacific. The high obesity rates, advanced healthcare infrastructure, and strong presence of key market players in North America are key factors contributing to its dominance. Meanwhile, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by the increasing prevalence of obesity, rising healthcare expenditure, and growing awareness about obesity treatment options.

Product Type Analysis

The obesity treatment devices market is segmented into various product types, including gastric bands, gastric balloons, electrical stimulation systems, gastric emptying systems, and others. Gastric bands are among the most commonly used devices, particularly due to their adjustability and reversibility. These bands are placed around the upper part of the stomach, creating a small pouch that limits food intake and promotes a feeling of fullness. The simplicity and effectiveness of gastric bands have made them a popular choice among both patients and healthcare providers.

Gastric balloons, another significant segment, are gaining traction due to their minimally invasive nature. These devices are inserted into the stomach via endoscopy and filled with saline to occupy space, thereby reducing hunger and promoting weight loss. Gastric balloons are typically used for short-term weight loss and are removed after six months. Their temporary nature and low risk of complications have made them an attractive option for patients seeking non-surgical weight loss solutions.

Electrical stimulation systems are innovative devices that stimulate the vagus nerve to control hunger signals and promote weight loss. These systems are implanted surgically and have shown promising results in clinical trials. The ability to modulate appetite without altering the digestive system

The global pediatric obesity management market is experiencing significant growth, driven by rising childhood obesity rates worldwide and increasing awareness of the long-term health consequences. This market, estimated at $15 billion in 2025, is projected to exhibit a robust Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated market value of $28 billion by 2033. Several factors contribute to this expansion, including the development of novel pharmacotherapies like setmelanotide and improved access to effective weight management programs. The increasing prevalence of comorbidities associated with pediatric obesity, such as type 2 diabetes and cardiovascular disease, further fuels market demand. Market segmentation reveals strong growth across various drug classes, including lorcaserin, liraglutide, and phentermine, reflecting diverse treatment approaches. Hospital pharmacies currently dominate the distribution channels, though the growing adoption of online pharmacies suggests a shift in distribution methods. Geographically, North America and Europe currently hold significant market share, but the Asia-Pacific region is expected to witness substantial growth due to rising obesity rates and increasing healthcare spending. However, challenges remain, including the high cost of treatment, potential side effects of medications, and the need for comprehensive lifestyle interventions that address the root causes of pediatric obesity. Further research and development focusing on safer and more effective treatments, coupled with improved public health initiatives, are crucial to effectively address this growing global health concern. The market’s growth is influenced by regional disparities. North America and Europe, with established healthcare infrastructure and higher awareness of pediatric obesity, are currently leading the market. However, rapidly developing economies in Asia-Pacific, particularly in countries like China and India, are exhibiting a significant rise in childhood obesity, creating substantial growth opportunities in the coming years. The competitive landscape includes major pharmaceutical companies like Pfizer, Roche, and GlaxoSmithKline, alongside specialized companies focused on pediatric obesity management. Strategic partnerships, mergers, and acquisitions are expected to further shape the market landscape. Successful market players will need to focus on developing innovative therapies, expanding access to treatment, and implementing comprehensive strategies that address the multifaceted nature of pediatric obesity, incorporating lifestyle changes alongside pharmacological interventions.

This table shows the percentage with (severe) overweight for the age group of 2 to 20 in total and by gender. The data comes from the annual health survey of Statistics Netherlands. Statistics Netherlands is conducting this survey with the aim of providing as complete an overview as possible of developments in health, medical consumption, lifestyle and preventive behavior of the Dutch population. The figures regarding overweight in children come from self-reports of height and weight. Research has shown that this leads to underreporting of (severe) overweight in adults. This has not yet been studied for children, but it is expected that this will also be underreported. For children up to the age of 12, the questions were answered by one of the child's carers (usually the mother). A generally accepted measure for determining overweight in adults aged 18 or older is the Body Mass Index (BMI). This BMI value is obtained by dividing body weight (in kilograms) by height (in metres) squared. Overweight occurs with an index of 25 kg/m² or higher. An index of 30 kg/m² is considered to be seriously overweight or obese. Criteria established by the World Health Organization were used to determine overweight and severe overweight in children. {Establishing a standard definition for child overweight and obesity worldwide: international survey. Tim J Cole, Mary C Bellizzi, Katherine M Flegal, William H Dietz. BMJ 2000;320:1-6}. The criteria have been chosen in such a way that from the age of 18 they correspond with the accepted values ​​for overweight (index => 25 kg/m²) and obesity (index => 30 kg/m²). Under the age of 18, limit values ​​have been determined per age and gender for the BMI above which there is overweight or obesity. Data available from: 1981 Status of the figures: Final Changes as of 4 August 2011 This table has been discontinued. When will new numbers come out? Discontinued.

This statistic displays the share of children between *** and nine years who are obese in Europe from 2015 to 2017, by gender . In this period, **** percent of girls and boys in Denmark were obese.

The global market for overweight patient care systems is experiencing robust growth, driven by rising obesity rates worldwide and an increasing demand for specialized healthcare solutions. The market, currently valued at approximately $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This expansion is fueled by several key factors, including technological advancements in bariatric equipment, a growing awareness of the health risks associated with obesity, and an increasing focus on patient safety and comfort during treatment and recovery. The aging global population also contributes significantly to market growth, as older adults are more prone to obesity-related health issues requiring specialized care. Major players like Stryker, Hill-Rom, and Invacare are driving innovation through the development of advanced, adaptable equipment designed to accommodate the specific needs of overweight patients. Segment-wise, the market is witnessing strong growth in areas like bariatric beds, patient lifts, and specialized wheelchairs. The increasing adoption of telehealth and remote patient monitoring solutions is also contributing to the overall market expansion. However, high initial investment costs for advanced equipment and the potential for reimbursement challenges in some healthcare systems pose constraints to market growth. Despite these hurdles, the long-term outlook for the overweight patient care system market remains positive, driven by sustained demand, technological innovation, and an expanding global healthcare infrastructure. Further geographic segmentation reveals strong growth in North America and Europe, fueled by robust healthcare spending and an established healthcare ecosystem, while emerging markets in Asia-Pacific are expected to exhibit high growth potential in the coming years.

The global market for long-term treatment drugs for obesity is experiencing robust growth, driven by rising prevalence of obesity and related comorbidities like type 2 diabetes and cardiovascular disease. The market, estimated at $15 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 10% from 2025 to 2033, reaching an estimated value of $40 billion by 2033. This expansion is fueled by several key factors including increased awareness of obesity as a serious health condition, the development of more effective and tolerable medications like GLP-1 receptor agonists (Semaglutide and Liraglutide) and other novel therapeutics, and expanding access to healthcare in emerging markets. The segment comprising GLP-1 receptor agonists currently dominates the market due to their efficacy in weight loss and improved glycemic control, but other drug classes, including Orlistat and emerging novel agents, are expected to contribute significantly to market growth in the coming years. The hospital and clinic application segments represent the largest share of the market, reflecting the importance of these settings for both diagnosis and management of obesity. Geographic distribution of the market reflects higher prevalence rates in developed nations. North America and Europe currently hold substantial market shares, driven by high healthcare expenditure and greater awareness. However, significant growth opportunities exist in Asia-Pacific, particularly in countries like China and India, due to rapidly increasing rates of obesity and expanding healthcare infrastructure. Despite the strong growth trajectory, the market faces challenges, including high drug costs, potential side effects associated with certain medications, and the need for long-term lifestyle changes in conjunction with pharmacological interventions. Regulatory hurdles and the development of biosimilars also pose potential constraints on market growth in the long term. Major players such as Novo Nordisk, Roche, GSK, Vivus, Arena, and Orexigen are actively involved in research, development, and commercialization, driving innovation and competition within the market.

The size of the Weight Loss Surgery Market in Europe market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 15.00% during the forecast period. Bariatric surgery is more commonly known as weight loss surgery, and for the time being it has emerged as a realistic solution for serious problems associated with obese individuals in Europe. Bariatric surgery is a procedure that involves modification of the digestive system for the purposes of reduced food intake and absorption, hence causing subsequent weight loss. There is the provision of the procedure for people whose BMI goes over 40 years and those with a BMI of 35 or more and who suffer from severe medical conditions. This includes type two diabetes, sleep apnea, or severe heart disease. The weight loss surgery market in Europe is highly booming due to several factors. The growing rates of obesity in the continent and health consequences caused by it increased the demand for effective management of weight. With the developments and improvements created in the sphere of surgical procedures and also care after surgery, bariatric operations have not only become less dangerous but also more efficient. In addition to the above, a good quality of life, diminution of chronic diseases, and an increased lifespan, which are part of the bariatric surgery benefits, support the growth of the market. A majority of European countries have come forward to the forefront in the weight loss surgery market. Germany boasts the world-class health care system and surgical experience; hence, it is the destination preferred for bariatric surgeries. Solid bariatric surgery programs exist in the United Kingdom, France, and Sweden, that attract patients from domestic and international markets. There are several advantages of weight loss surgery; however, it must be remembered that it is not a magic solution for losing weight. Commitment to a lifestyle change, which embodies alteration in diet and exercise, can be an arduous task for patients who have to carry it long after the surgery. This surgical procedure is not without its risks and complications-infection, for instance, to possible internal bleeding and nutrient deficiencies. All of these being considered, therefore, great care and more so consultation with a qualified health professional are paramount before one makes a decision on this approach to weight loss surgery. Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Lack of Knowledge and Awareness in the Region, High Cost of Surgery. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.